RxDoctor Payments Data

Daniel McCammon, MD

Endocrinology, Diabetes & Metabolism · Knoxville, TNNPI 1073518890

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,343 of the $9,066 with a category attached, or 81.0%. It is spread thinly across 49 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.

$9,066in general payments, 2019–2025

Across 419 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$2K
  • Novo Nordisk$1K
  • Abbott$725
  • Dexcom, Inc.$605
  • Amgen$471
  • Lilly USA, LLC$447
  • plus $4K from 43 others

What the payments were for

  • Speaking & faculty fees$1,65018%
  • Food & beverage$7,34381%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,066 in reported general payments places this provider in the 65th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee

Medicare billing

Part B allowed, 2024
$102,941
Medicare patients
318
Services billed
3,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide16$91,781
SynthroidLevothyroxine Sodium114$9,287
Levothyroxine Sodium776$7,054
Novolog FlexpenInsulin Aspart11$6,484
NovologInsulin Aspart14$6,060
Testosterone16$3,347
Hydrocortisone37$2,128
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,675
Desmopressin AcetateDesmopressin (Nonrefrigerated)11$1,130
Cabergoline24$1,090
Methimazole105$895
Calcitriol26$742
Testosterone Cypionate14$700
Prednisone12$211
Alendronate Sodium27$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$447$91,78116 claims
AbbVieSynthroid$58$9,287114 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$7,054776 claims
Novo NordiskNovolog$1,309$6,06014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

Other endocrinology, diabetes & metabolism in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →